Analysts expect over 2021 decreasing revenue Morphosys

Tomorrow Morphosys will publish its past quarters results. For this year the company from Planegg could earn a total revenue around 167.22 million euros. This is according to the average of the analysts' estimates. This is rather significant lower than 2021's revenue of 327.7 million euros.

Historical revenues and results Morphosys plus estimates 2021

The analysts expect for 2021 a net loss of 278 million euros. For this year the consensus of Morphosys 's result per share is a loss of 7.37 euros. The PE-ratio therefore is -3.15.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is an attractive 2.64 percent.

Latest estimates around 45 euros

The latest 3 recommendations for the biotech company were provided by HSBC , Citigroup and Goldman Sachs .

Based on the current number of outstanding shares Morphosys 's market capitalization 735.87 million euros. -72

At 17.37 the stock trades 2.15 percent lower at 23.19 euros.

Price data Morphosys 2007-2021

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.